330792-69-3

Basic information

• Product Name: Propanedinitrile, 2-[Methoxy(4-phenoxyphenyl)Methylene]-
• Synonyms: Propanedinitrile, 2-[Methoxy(4-phenoxyphenyl)Methylene]-;2-(Methoxy(4-phenoxyphenyl)Methylene)Malononitrile;1,1-Dicyano-2-methoxy-2-(4-phenoxyphenyl)ethene;2-[Methoxy(4-phenoxyphenyl)methylene]propanedinitrile;2-[(4-phenoxy-phenyl)-methoxy-methylene]-malononitrile;Intermediate of Ibrutinib, Note separate 2-[(4-phenoxy-phenyl)-methoxy-methylene]-malononitrile
• CAS NO: 330792-69-3
• Molecular Formula: C₁₇H₁₂N₂O₂
• Molecular Weight: 276.28938
• Mol File: 330792-69-3.mol
• Article Data: 40

Chemical Properties

• Boiling Point: 471.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.199±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Propanedinitrile, 2-[Methoxy(4-phenoxyphenyl)Methylene]-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedinitrile, 2-[Methoxy(4-phenoxyphenyl)Methylene]-(330792-69-3)
• EPA Substance Registry System: Propanedinitrile, 2-[Methoxy(4-phenoxyphenyl)Methylene]-(330792-69-3)

Safety Data

• Hazardous Substances Data: 330792-69-3(Hazardous Substances Data)

Usage

General Description

Propanedinitrile, 2-[Methoxy(4-phenoxyphenyl)Methylene]-, also known as 2-(4-phenoxybenzylidene)malononitrile, is an organic compound with the chemical formula C17H13NO2. It is a yellow crystalline powder that is commonly used in the synthesis of organic compounds and as a chemical reagent in laboratory experiments. This chemical is also known for its use in the production of dyes, pharmaceuticals, and agrochemicals. Additionally, it has been found to exhibit biological activities, making it a potential candidate for various applications in the field of medicine and biotechnology.

Upstream product

• 1623-95-6 4-phenoxybenzoyl chloride 
• 109-77-3 malononitrile 
• 149-73-5 trimethyl orthoformate 
• 77-78-1 dimethyl sulfate 
• 459-57-4 4-fluorobenzaldehyde 
• 330792-68-2 2-[hydroxy-(4-phenoxy-phenyl)-methylene]-malononitrile 
• 108-95-2 phenol 
• 619-44-3 methyl 4-iodobenzoate 
• 21218-94-0 methyl 4-phenoxybenzoate 
• 2215-77-2 4-Phenoxybenzoic acid 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 1207476-93-4 C₂₄H₁₉N₃O₂ 
• 330792-70-6 5-amino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile 
• 1418272-57-7 C₃₃H₃₉N₇O₅ 
• 1418270-10-6 (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)-4-(2-methoxyethylamino)but-2-en-1-one 
• 1418272-59-9 C₂₅H₂₃BrN₆O₂ 
• 1418272-63-5 C₃₃H₃₇N₇O₄ 
• 1418270-73-1 (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)-4-(cyclopropylamino)but-2-en-1-one 
• 1418270-14-0 (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)-4-((2-methoxyethyl)(methyl)amino)but-2-en-1-one 
• 1418272-69-1 C₂₃H₁₆N₆O₃ 
• 1418272-70-4 C₂₈H₂₄N₆O₅ 
• 1418272-71-5 C₂₈H₂₆N₆O₃ 
• 1418272-72-6 C₂₉H₂₈N₆O₃ 
• 1418270-24-2 (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)-4-(methyl(pyridin-2-yl)amino)but-2-en-1-one 
• 1418270-28-6 (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)-4-(dicyclopropylamino)but-2-en-1-one 

Relevant articles and documents

PROCESSES AND INTERMEDIATES FOR PREPARING A BTK INHIBITOR

Disclosed is a process for the preparation of certain intermediates, e.g. process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, in an enantioenriched form, which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.

Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning

Potent covalent inhibitors of Bruton's tyrosine kinase (BTK) based on an aminopyrazole carboxamide scaffold have been identified. Compared to acrylamide-based covalent reactive groups leading to irreversible protein adducts, cyanamide-based reversible-covalent inhibitors provided the highest combined BTK potency and EGFR selectivity. The cyanamide covalent mechanism with BTK was confirmed through enzyme kinetic, NMR, MS, and X-ray crystallographic studies. The lead cyanamide-based inhibitors demonstrated excellent kinome selectivity and rat pharmacokinetic properties.

Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor

Therapeutic combinations of a proteasome inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of a proteasome inhibitor and a BTK inhibitor and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.